Regulation of PD-L1 expression in the tumor microenvironment

Ming Yi¹, Mengke Niu¹,², Linping Xu², Suxia Luo²* and Kongming Wu¹,²*

Abstract
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.

Keywords: Cancer immunology, PD-L1, PD-1, Transcriptional regulation, Post-transcriptional modification

Background
In physiological conditions, the activities of T cells are intricately regulated. T cell immunity selectively eliminates pathogens and abnormal cells but avoids attacking normal cells, termed immune homeostasis [1]. Programmed cell death-1 (PD-1, which is encoded by PDCD1) and programmed death-ligand 1 (PD-L1, which is encoded by CD274) are vital proteins in maintaining immune homeostasis [2]. The PD-1/PD-L1 pathway restrains the hyperactivation of immune cells and prevents autoimmune diseases [3]. However, in the tumor microenvironment (TME), the PD-1/PD-L1 axis is hijacked by cancer cells to escape immune surveillance [4]. The overexpressed PD-L1 on cancer cells binds to the PD-1 on tumor-infiltrating lymphocytes (TILs), which counteracts the TCR-signaling cascade by phosphorylating SHP-2 [5, 6]. As a result, T cell activation is impaired.

Apart from cancer cells, some other types of cells in the TME, such as macrophages, dendritic cells (DCs), activated T cells, as well as cancer-associated fibroblasts, also express PD-L1 [7]. These components orchestrate an immunosuppressive microenvironment, supporting tumor growth.

Inhibiting the PD-1/PD-L1 signaling is a feasible strategy to normalize the dysregulated TME [8]. Up to now, α-PD-1/PD-L1 treatments have exhibited potent anti-tumor activities in various cancers, such as melanoma, non-small cell lung cancer (NSCLC), gastric cancer, liver cancer, uterine cancer, lymphoma, and all MSI-high cancers [2, 9–19]. Commonly, the PD-L1 protein level is the primary standard to select patients who are more likely to respond to α-PD-1/PD-L1 treatments [20, 21]. However, the PD-L1 level is determined by several factors, which results in the different significances of PD-L1 positivity or negativity. The PD-L1 positivity might result from immune response-induced PD-L1 expression or oncogenic constructive PD-L1 upregulation [22]. For the latter, in the absence of pre-existing immune response, patients with PD-L1 positive tumors commonly are resistant to α-PD-1/PD-L1 therapies [20].

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
On the contrary, patients with PD-L1 negative tumors might respond to α-PD-1/PD-L1 treatment when undergoing combination therapies that promote T cell infiltration [22]. Therefore, an in-depth understanding of PD-L1 regulation is valuable for efficacy prediction and patient selection. In this review, we summarized the latest advances of PD-L1 regulation, including genomic alterations, epigenetic modification, transcriptional regulation, post-transcriptional modification, and post-translational modification. Moreover, we discussed the potential applications of these findings in the clinic.

**Genomic alterations of CD274**

In some cancers such as classical Hodgkin lymphoma and small-cell lung cancer, the copy number of chromosome 9p24.1 (where CD274 resides) was increased [23, 24]. The chromosome rearrangement caused CD274 amplification without influences on the open reading frame (Fig. 1) (Table 1) [24]. Besides, in mediastinal large B-cell lymphoma, the increased transcriptional expression of CD274 was related to an adjacent ectopic promoter or enhancer by translocation [25]. These findings indicated that genomic alterations contributed substantially to cancer immune escape, which might be a potential biomarker for patient selection.

---

**Fig. 1** The regulators of PD-L1 expression. PD-L1 abundance is regulated by genomic alterations (amplification or translocation), epigenetic modifications (methylation of histone or CpG island, and histone acetylation), transcriptional regulation (inflammatory stimuli and oncogenic signals), post-transcriptional regulation (miRNA, the status of 3′-UTR, RAS, and Angiotensin II), and post-translational modification (ubiquitination, phosphorylation, glycosylation, palmitoylation). H3K4me3: tri-methylation of histone H3 on lysine 4; H3K27me3: tri-methylation of histone H3 on lysine 27; EGFR: epidermal growth factor receptor; IRF: interferon-responsive factor; IFN: interferon; DSB: double-strand break; GSK3β: glycogen synthase kinase 3β; PI3K: phosphoinositide 3-kinase; NF-κB: Nuclear factor kappa-B; HIF-1α: hypoxia-inducible factor-1α; ALK: Anaplastic lymphoma kinase; ER: endoplasmic reticulum.
| Regulatory stage          | Regulator                                      | The change of PD-L1 | Cancer type                                                                 | References       |
|--------------------------|------------------------------------------------|---------------------|-----------------------------------------------------------------------------|------------------|
| Genomic alterations      | Gene amplification or translocation            | Up                  | Classical Hodgkin lymphoma; Small-cell lung cancer; Large B-cell lymphoma    | [23–25]          |
| Epigenetic regulation    | H3K4me3                                        | Up                  | Pancreatic cancer                                                           | [27]             |
|                          | H3K27me3                                       | Down                | Hepatocellular carcinoma                                                    | [29]             |
|                          | Methylation of some CpG loci in CD274 promoter | Down                | Melanoma; Head and neck squamous cell carcinomas; Colorectal cancer         | [33–35]          |
| Transcriptional regulation | Histone acetylation                            | Up                  | Drug-resistant cancer cells;                                               | [39]             |
|                          | IFN-α, IFN-β, IFN-γ                            | Up                  | Melanoma; Hepatocellular carcinoma; Gastric carcinoma                      | [44, 46, 48]     |
|                          | IL-6                                           | Up                  | Prostate cancer; Hepatocellular carcinoma; Glioblastoma; Non-small cell lung cancer | [50–53]          |
|                          | TNF-α                                          | Up                  | Prostate cancer; Colon cancer; Renal cell carcinoma                        | [54, 55]         |
|                          | IL-10                                          | Up                  | Oral squamous cell carcinoma                                                | [56]             |
|                          | IL-27                                          | Up                  | Epithelial ovarian cancer; Prostate cancer; Non-small cell lung cancer     | [57]             |
|                          | TGF-β                                          | Up                  | Lung cancer                                                                 | [60, 61]         |
|                          | EGFR                                           | Up                  | Lung cancer                                                                 | [62]             |
|                          | MAPK                                           | Up                  | Lung cancer; Melanoma; Pancreatic cancer; Triple-negative breast cancer     | [67–70]          |
|                          | PTEN                                           | Down                | Triple-negative breast cancer                                               | [74]             |
|                          | PI3K                                           | Up                  | Gastric cancer; Her2-overexpressing cell lines; Colorectal cancer; Head and neck squamous cell carcinomas; Non-small cell lung cancer | [75–79]          |
|                          | JAK-STAT                                       | Up                  | Natural killer/T-cell lymphoma; Non-small cell lung cancer; Triple-negative breast cancer | [80–83]          |
|                          | NF-κB                                          | Up                  | Natural killer/T-cell lymphoma; Gastric carcinoma; Non-small cell lung cancer; Triple-negative breast cancer | [84, 87–90]     |
|                          | HIF-1                                          | Up                  | Prostate cancer; Breast cancer; Nasopharyngeal carcinoma                   | [92, 93]         |
|                          | Myc                                            | Up                  | Leukemia and lymphomas; Melanoma; Non-small cell lung cancer; Hepatocellular carcinoma; Renal cell carcinoma; Colorectal carcinoma; Esophageal squamous cell carcinoma; Pancreatic cancer | [96–99]          |
|                          | ALK                                            | Up                  | Non-small cell lung cancer; Anaplastic large cell lymphoma                  | [103, 104]       |
|                          | Met                                             | Up                  | Non-small cell lung cancer                                                  | [107–110]        |
|                          | BRD4                                            | Up                  | Ovarian cancer                                                              | [112]            |
Epigenetic regulations

Epigenetic regulations such as methylation and histone acetylation determine the PD-L1 expression as well (Fig. 1). Tri-methylation of histone H3 on lysine 4 (H3K4me3) is generally believed as a histone modification promoting gene transcriptions [26]. In pancreatic cancer, MLL1 protein could bind to the CD274 promoter to catalyze H3K4me3, leading to the increased expression of PD-L1 [27]. In agreement, the MLL1 inhibitor had a synergistic effect with α-PD-1/PD-L1 therapy [27]. On the contrary, tri-methylation of histone H3 on lysine 27 (H3K27me3) relates to transcription suppression [28]. In hepatocellular carcinoma, enhancer of zeste homolog 2 negatively regulated PD-L1 expression by promoting H3K27me3 [29].

Besides the methylation of histone, the methylation of DNA at CpG islands regulated PD-L1 expression [30]. Inhibiting methylation of DNA by DNA methyltransferase inhibitors (DNMTis) increased PD-L1 level in cancer cells [31, 32]. The authors assumed that DNMTis elevated the expression of hypermethylated endogenous retroviruses in cancer cells, which might activate the innate immune response and lead to IFN-γ-stimulated PD-L1 expression [30]. Moreover, the methylation of some specific CpG loci in the CD274 promoter determined the level of CD274 mRNA [33–35]. In NSCLC, TGF-β1 impaired the activity of DNMTs, demethylated the CD274 promoter, and increased PD-L1 expression [36]. Notably, in patients with recurrent gastric cardia adenocarcinoma, PD-L1 expression was reduced after

### Table 1 (continued)

| Regulatory stage                  | Regulator                        | The change of PD-L1 | Cancer type                                                                 | References |
|-----------------------------------|----------------------------------|---------------------|------------------------------------------------------------------------------|------------|
| Post-transcriptional regulation   | miR-148a-3p                      | Down                | Colorectal cancer                                                            | [116]      |
|                                   | miR-873                          | Down                | Breast cancer                                                                | [117]      |
|                                   | miR-34a                          | Down                | B-cell lymphoma; Acute myeloid leukemia                                        | [118, 126] |
|                                   | miR-200 family                   | Down                | Non-small cell lung cancer; Hepatocellular carcinoma                          | [119, 120] |
|                                   | miR-142-5p                       | Down                | Pancreatic cancer                                                            | [121]      |
|                                   | miR-424                          | Down                | Ovarian cancer                                                               | [122]      |
|                                   | miR-214                          | Down                | Diffuse large B-cell lymphoma                                                | [123]      |
|                                   | miR-497-5p                       | Down                | Clear cell renal cell carcinoma                                              | [124]      |
|                                   | miR-140                          | Down                | Non-small cell lung cancer                                                   | [125]      |
|                                   | miR-23a-3p/PTEN axis              | Up                  | Liver Cancer                                                                 | [127]      |
|                                   | miR-200a/PTEN axis                | Up                  | Osteosarcoma                                                                | [128]      |
|                                   | miR-27a-3p/ MAGI2/PTEN axis       | Up                  | Breast cancer                                                                | [129]      |
|                                   | miR-145/c-Myc axis                | Down                | Ovarian cancer                                                               | [130]      |
|                                   | miR-18a/ PTEN, WNK2, SOX6 axis    | Up                  | Cervical cancer                                                              | [131]      |
|                                   | miR-BART5/PIAS3/pSTAT3            | Up                  | Gastric cancer                                                               | [133]      |
|                                   | RAS-tristetraprolin              | Up                  | RAS mutant cancer                                                            | [135]      |
|                                   | Angiotensin II/human antigen R    | Up                  | Non-small cell lung cancer                                                   | [136]      |
| Post-translational modification   | Ubiquitination                    | Down                | Multiple cancers                                                             | [138, 141, 142] |
|                                   | Y112 phosphorylation             | Up                  | Hepatocellular carcinoma                                                     | [143]      |
|                                   | S195 phosphorylation             | Down                | Breast cancer                                                                | [144]      |
|                                   | T180 and S184 phosphorylation    | Down                | Breast cancer                                                                | [145]      |
| Glycosylation                     | Up                               | Breast cancer; Glioma                                                        | [145, 149, 150] |
| Palmitoylation                    | Up                               | Breast cancer; Colon cancer                                                  | [151, 152] |

H3K4me3 tri-methylation of histone H3 on lysine 4, H3K27me3 tri-methylation of histone H3 on lysine 27, EGFR epidermal growth factor receptor, MAPK mitogen-activated protein kinase, PTEN phosphatase and tensin homolog, PI3K phosphoinositide 3-kinase, NF-κB nuclear factor kappa-B, HIF-1α hypoxia-inducible factor-1α, ALK anaplastic lymphoma kinase, DSB double-strand break
α-PD-1/PD-L1 treatment [37]. Further investigations indicated that the CD274 promoter was more hypermethylated in the relapsed tumors than in the primary tumors without α-PD-1/PD-L1 treatment [37]. In murine tumor models, the combination therapy of hypomethylating agent azacytidine and α-PD-1 showed a more significant antitumor effect than α-PD-1 monotherapy [37].

Histone acetylation is an epigenetic modification enhancing gene transcription [38]. In some drug-resistant cancer cells, hyperactivated JNK/c-Jun signaling suppressed the histone deacetylase 3 (HADC3) expression, thereby elevating the histone H3 acetylation of the CD274 promoter [39]. The HADC inhibitor had a synergistic effect with α-PD-1 in the B16F10 tumor model [40]. Furthermore, HADC inhibitor-mediated PD-L1 upregulation was observed in other types of cancers [41, 42]. These findings provide a rationale to combine α-PD-1/ PD-L1 treatments with HDAC inhibitors.

Transcriptional regulation

Inflammatory Signaling

Interferon (IFN) and IL-6

As a negative feedback for inflammation, PD-L1 could be upregulated by multiple inflammatory signaling pathways to restrain T cells’ hyperactivity (Fig. 1). Generally believed, IFN-γ is the prominent stimulator contributing to the inducible PD-L1 expression [43].

During cancer progression, the IFN-γ-derived PD-L1 promotes cancer immune escape [3]. In the TME, activated T cells and NK cells generate most IFN-γ. Then, IFN-γ binds to type II interferon receptor, activating the JAK-STAT signaling (mainly through STAT1) [44, 45]. Subsequently, the expression of several transcriptional factors is upregulated, especially interferon-responsive factors (IRFs). IRF-1 is the vital downstream component of STAT1 upon IFN-γ treatment [46, 47]. In hepatocellular carcinoma, it was identified that two elements (IRE1/2) in the 5′-flanking region of the CD274 promoter were the binding sites of IRF-1, which participated in regulating PD-L1 transcription [48]. Notably, the intactness of JAK-STAT-IRF1 pathway is also related to the response to α-PD-1/PD-L1 therapy. The effect of α-PD-1/ PD-L1 treatment is limited in tumors with mutations in JAK1 and JAK2 [49]. It was speculated that these tumors might not rely on the PD-1/PD-L1 pathway to escape immune surveillance [49].

Besides IFN-γ, other inflammatory stimuli such as IFN-α, IFN-β, and IL-6 could induce PD-L1 expression as well. However, IFN-α and IFN-β had a more significant effect on PD-L2 regulation than PD-L1 regulation [44]. In prostate cancer, the IL-6-JAK-STAT3 pathway promoted PD-L1 expression and led to the resistance to immune killing [50]. Moreover, in hepatocellular carcinoma, increased IL-6 activated the STAT3/c-MYC/miR-25-3p pathway, which resulted in the decreased protein tyrosine phosphatase receptor type O (PTPRO) [51]. The downregulated PTPRO-enhanced PD-L1 expression by deregulating the activation of JAK2-STAT1/3 [51]. Furthermore, the glioblastoma-derived IL-6 could induce the local and systemic myeloid PD-L1 expression by STAT3 phosphorylation [52]. Besides, in lung cancer, it was detected that IL-6-derived PD-L1 expression was related to multiple pathways, especially the MEK-ERK signaling [53].

Other inflammatory signals

Tumor necrosis factor-α (TNF-α) increased CD274 mRNA by activating nuclear factor kappa-B (NF-κB) pathway [54]. In renal cell carcinoma, TNF-α cooperated with IL-4 to enhance CD274 transcription by activating NF-κB, IKK, and STAT6 [55]. Moreover, in oral squamous cell carcinoma, the IL-10 level in the TME was positively correlated to the abundance of PD-L1 on tumor-associated macrophages [56]. Blocking IL-10 suppressed PD-L1 expression [56]. Furthermore, in several human cancer cells, IL-27 increased CD274 transcription by promoting the tyrosine phosphorylation of STAT1 and STAT3 [57]. The effect of TGF-β on PD-L1 regulation is still unclear. Although some previous studies indicated that TGF-β downregulated PD-L1 expression in renal tubular epithelial cells and monocytes [58, 59], TGF-β mainly had a positive impact on the PD-L1 expression in the TME. In NSCLC cells, exogenous TGF-β increased the CD274 transcription probably by Smad-binding elements [60]. The expression of phosphorylated-Smad2 was significantly increased in PD-L1 positive NSCLC patients [60]. Apart from cancer cells, TGF-β could increase PD-L1 expression on DCs in the TME [61].

Oncogenic Signaling

Besides inflammatory stimuli, growing evidence suggests that hyperactive oncogenic pathways play a vital role in PD-L1 expression (Fig. 1). Therefore, α-PD-1/ PD-L1 therapies might have a synergistic effect with oncogenic signal-targeting treatments.

Epidermal Growth Factor Receptor (EGFR)

In lung epithelial cells, the mutated EGFR pathway (EGFR T790M) increased PD-L1 expression [62]. For lung cancer cells, PD-L1 expression was impaired after EGFR tyrosine kinase inhibitor (TKI) treatment [62]. In murine EGFR-driving lung cancer models, α-PD-1 effectively reversed T cell exhaustion and retarded tumor growth [62]. The results indicated that the mutant EGFR pathway facilitated tumor to escape from immune surveillance [62]. However, a clinical study showed that
EGFR-mutant NSCLC patients tended to resist α-PD-1 therapy [63]. The authors found that although some EGFR-mutant NSCLCs were PD-L1 positive, the concurrent PD-L1 upregulation and abundant TILs were rare [63]. The lack of a pre-existing inflammatory TME might limit the effect of α-PD-1/PD-L1 treatment [63]. The low response rate in EGFR-mutant patients was reported by other investigators [64,65].

Mitogen-activated protein kinase (MAPK)

MAPK is a well-studied oncogenic pathway, which counts for nearly 40% of human cancer cases [66]. According to TCGA database, the CD274 mRNA level was significantly positively related to RAS- or MEK-activation scores in NSCLC patients [67]. In lung adenocarcinoma cells, activating EGF-MAPK signaling increased the mRNA and protein levels of PD-L1 [67]. Inhibiting MAPK signaling by MEK inhibitor (Selumetinib) counteracted the EGF- and IFN-γ-stimulated upregulation of CD274 mRNA and PD-L1 protein [67]. In melanoma cells, the activated NRAS-RAF-MEK1/2-ERK-c-Jun axis enhanced the transcription of CD274 [68]. Moreover, in pancreatic cancer, myeloid cells induced PD-L1 expression on tumor cells by activating EGF-MAPK pathway [69]. After MEK inhibitor treatment, the levels of p-ERK and PD-L1 were decreased, and this reduced PD-L1 led to a higher sensitivity to α-PD-1 treatment in murine pancreatic tumors [69].

On the contrary, in murine breast cancer cells, suppressing MAPK signaling by Trametinib (a MEK inhibitor) potentiated the IFN-γ-stimulated upregulation of PD-L1 and major histocompatibility complex (MHC) [70]. Furthermore, in cancer cell lines, including KYSE30, TE-1, MKN7, PC-9, SNU-475, OE19, and BT-549, there was no significant alteration when cancer cells were treated with MAPK inhibitor [71]. Besides, the MAPK inhibitor had no significant impact on IFN-γ-stimulated PD-L1 expression [71]. The role of MAPK pathway in PD-L1 regulation might depend on cell types [72].

PTEN/PI3K-AKT pathway

As a well-studied tumor suppressor, PTEN is a vital regulator of the oncogenic signaling pathway PI3K-AKT [73]. PTEN loss and PI3K activation have been identified in multiple types of cancers, including hepatocellular carcinoma, prostate cancer, and breast cancer [73]. Deficient PTEN was detected in nearly half of PD-L1 positive triple-negative breast cancer samples [74]. Knocking down PTEN resulted in a rise of PD-L1 expression [74]. Moreover, activating the PI3K-AKT pathway in gastric cancer cells increased PD-L1 abundance, while PI3K inhibitor (LY294002) reduced PD-L1 level [75]. Besides, in head and neck cancer cells, melanoma cells, colorectal cancer cells, and Her2-amplified cancer cells (SNU216, NCI-N87, and SKBR3), PD-L1 expression was suppressed by PI3K inhibition [68,76–78]. Moreover, inhibiting mTOR (the downstream of PI3K-AKT) by rapamycin reduced PD-L1 level in NSCLC cells [79].

JAK-STAT pathway

Mutations in JAK1, JAK3, and STAT3 were prevalent in mature T-cell lymphomas [80]. Some STAT3 mutations, such as p.E616K, increased the STAT3 phosphorylation and STAT3-mediated transcription [80]. In the meanwhile, silencing STAT3 or STAT3 inhibitor reduced PD-L1 expression [80]. Further chromatin immunoprecipitation qPCR assay indicated the p.E616K mutation might increase the transcription activity of CD274 promoter by a stronger STAT3 binding [80]. Besides, in breast and lung cancer cells, the PD-L1 expression was hampered by JAK and STAT3 inhibitors [81–83].

NF-κB pathway

Activated NF-κB signaling was related to the high level of PD-L1 in several cancers [36,84–88]. Multiple oncogenic signals could impair immune surveillance by activating the NF-κB-PD-L1 axis. In lung cancer cells, overexpressed MUC1-C increased the occupancy of NF-κB p65 in CD274 promoter, which enhanced CD274 transcription [89]. Besides, in breast cancer, reactive oxygen species (ROS) inducers (paclitaxel, glutathione synthesis inhibitor, and buthionine sulfoximine) led to the accumulation of ROS, subsequently activating the downstream NF-κB pathway [90]. In a murine breast cancer model, paclitaxel treatment induced PD-L1 upregulation in tumor-associated macrophages by the NF-κB p65-PD-L1 pathway [90].

Hypoxia-inducible factor-1 (HIF-1)

Hypoxia facilitates the drug resistance and distant metastasis of tumor cells [91]. Besides, a hypoxic TME undermines host immunity activities and contributes to immune escape [92]. Hypoxia upregulated PD-L1 expression by HIF-1α [92]. The hypoxia-induced upregulation of CD274 mRNA was hampered when HIF-1α was silenced [92]. Further investigations suggested the cellular colocalization of PD-L1 and HIF-1α [92]. In the meanwhile, inhibiting HIF-1 signaling could reduce PD-L1 expression in multiple types of cancers [93,94].

Myc

As a transcription factor regulating cell differentiation, proliferation, and apoptosis, Myc is overexpressed in various cancers [95]. Knocking down or inhibiting Myc in cancer cells reduced CD274 mRNA and PD-L1 protein [96–99]. The results of the ChIP-seq assay showed that...
Myc could bind to the CD274 promoter [96]. However, in some particular types of cancer, Myc negatively regulated PD-L1 expression. In hepatocellular carcinoma cells, inhibiting Myc increased the IFN-γ-stimulated PD-L1 expression [100]. Besides, in the murine MycCaP tumor model, Myc inhibitor treatment promoted T cell infiltration, enhanced antitumor immune response, but simultaneously upregulated PD-L1 expression [101]. This PD-L1 upregulation was induced by immune response [101].

**Anaplastic lymphoma kinase (ALK)**

Chromosomal rearrangements in the ALK gene are an oncogenic driver for NSCLC [102]. In various NSCLC cell lines, the CD274 mRNA and PD-L1 protein levels were higher in cells with echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion [103]. Ectopic expressing EML4-ALK protein or blocking ALK phosphorylation positively or negatively regulated PD-L1 expression [103]. Besides, inhibiting PI3K-AKT or MEK-ERK pathways reversed the EML4-ALK-induced PD-L1 expression [103]. Apart from NSCLC, the PD-L1 level was higher in ALK-positive systemic anaplastic large cell lymphoma [104].

**Met**

Alterations in the Met gene were reported in multiple types of cancers [105, 106]. In primary lung cancer tissues, the level of PD-L1 was positively correlated to the Met-amplification [107, 108]. In a microarray assay, inhibiting or knocking down Met substantially reshaped the expression of several immune-related genes, including CD274 [109]. On the contrary, activating Met by hepatocyte growth factor increased PD-L1 expression [109, 110].

**BRD4**

As a member of the bromodomain and extraterminal ( BET) family, BRD4 acts as a super-enhancer of oncogenes [111]. In ovarian cancer cells, BET inhibitor reduced PD-L1 expression in a time- and dose-dependent manner [112]. Further, the ChIP assay showed a significant association of CD274 promoter and BRD4 [112]. After BET inhibitor treatment, the associations of CD274 promoter-BRD4 and CD274 promoter-RNA Pol II were decreased, which contributed to the downregulated CD274 transcription [112]. Besides, it was validated that BET inhibitor suppressed CD274 transcription by reducing the BRD4 occupancy at CD274 promoter, independent of c-Myc [113].

**DNA double-strand break (DSB) repair pathway**

After inducing DSB by ionizing radiation, PD-L1 expression was increased in multiple cancer cell lines [114]. In contrast, paclitaxel (a non-DNA damaging agent) treatment had no significant impact on PD-L1 expression [114]. DSB-activated ATM-ATR-ChK1-STAT1/3-IRF1 pathway led to the downstream PD-L1 upregulation [114].

**Post-transcriptional regulation**

**microRNA (miRNA)**

Cancer-derived miRNA is a vital post-transcriptional regulator for PD-L1 expression in the TME (Fig. 1) [115]. In colorectal cancer cells with mismatch repair deficiency or microsatellite instability-high, miR-148a-3p was decreased while PD-L1 was increased [116]. The results of the co-transfection of miR-148a-3p mimic and wild-type or mutant CD274 3′-untranslated region (UTR) luciferase reporter indicated that CD274 mRNA was the direct target of miR-148a-3p [116]. Furthermore, in breast cancer cells, miR-873 suppressed PD-L1 expression by targeting CD274 mRNA [117]. Up to now, it was identified that CD274 mRNA was the direct target of multiple oncogenic miRNAs such as miR-34a, miR-200 family, miR-424, miR-214, miR-497-5p, miR-140 [118–120].

Besides, some cancer-derived miRNAs indirectly regulated PD-L1 expression [127–129]. In ovarian carcinoma cells, miR-145 downregulated PD-L1 by targeting c-Myc [130]. In cervical cancer cells, increased PD-L1 was related to the upregulation of miR-18a [131]. miR-18a promoted PD-L1 expression by targeting PTEN (inhibitor of PI3K-AKT), WNK2 (inhibitor of MAPK), and SOX6 (inhibitor of Wnt/β-catenin) [131]. Similarly, hepatocellular carcinoma cell-derived miR-23a-3p enhanced PD-L1 expression in macrophages via targeting PTEN [127]. In NSCLC cells, miR-3127-5p promoted PD-L1 expression by activating STAT3 [132]. Moreover, in gastric cancer, miR-BART5-5p increased PD-L1 by targeting PIAS3 (inhibitor of STAT3) [133].

**The stability of CD274 mRNA**

The variations in the 3′-UTR affected the stability of CD274 mRNA [134]. Disturbing the 3′-UTR of CD274 mRNA by Crisper-Cas9 could stabilize CD274 mRNA [134]. Besides, oncogenic RAS activation inhibited tristetraprolin (AU-rich element-binding protein) by kinase MK2, stabilizing CD274 mRNA [135]. As a result, RAS activation increased PD-L1 expressed on cancer cells [135]. Moreover, in NSCLC, Angiotensin II increased the stability of CD274 mRNA and induced PD-L1 expression by human antigen R (also known as HuR, an AU-rich element-binding protein) [136].
Post-translational modification

Post-translational modifications, including ubiquitination, phosphorylation, glycosylation, palmitoylation, and SUMOylation, play a vital role in regulating protein stability, activation, localization, as well as interaction [137]. Aberrant post-translational modification patterns participated in PD-L1 upregulation in the TME (Fig. 1) [138].

Ubiquitination

Ubiquitination is related to proteasome-mediated protein degradation [139]. In a broad range of cancer cells, CMTM6 maintained PD-L1 expression by reducing PD-L1 ubiquitination and increasing PD-L1 half-life [138, 140]. Moreover, cyclin D/cyclin-dependent kinase 4 (CDK4) promoted PD-L1 ubiquitination by SPOP/Cullin 3-SPOP E3 ligase [141]. CDK4/6 inhibitor treatment increased PD-L1 abundance, which provided a potential for the combining therapy of CDK4/6 inhibitors and α-PD-1/PD-L1 agents [141]. Besides, the TNF-α-NF-κB pathway inhibited PD-L1 ubiquitination via upregulating COP9 signalosome 5 (CSN5) [142]. Inhibiting CSN5 impaired PD-L1 expression and sensitized tumor cells to the following immunotherapy [142].

Phosphorylation

IL-6-activated JAK1 promoted the phosphorylation of PD-L1 protein (Tyr112) [143]. Subsequently, Tyr112-phosphorylated PD-L1 recruited STT3A (N-glycosyltransferase) to catalyze the PD-L1 glycosylation [143]. Activating the IL-6-JAK1 signaling elevated PD-L1 stability by this phosphorylation modification [143]. Blocking the IL-6-JAK1 axis had a synergistic effect with α-Tim-3 treatment in murine tumor models [143]. Besides, metformin-activated AMP-activated protein kinase promoted the phosphorylation of PD-L1 (S195) [144]. The S195 phosphorylation led to the aberrant PD-L1 glycosylation, which undermined the PD-L1 translocation from endoplasmic reticulum to Golgi [144]. Apart from hampering the translocation of PD-L1 to cell membrane, the S195 phosphorylation enhanced endoplasmic reticulum-associated PD-L1 degradation [144]. The combination therapy of metformin and α-cytotoxic T Lymphocyte antigen 4 (CTLA-4) exhibited a robust antitumor activity [144]. Moreover, glycosyn thase kinase 3β (GSK3β) decreased the level of PD-L1 by promoting phosphorylation-dependent proteasome degradation [145, 146].

Glycosylation

Glycosylation modification is related to protein stability [147, 148]. The N192/200/219 glycosylation stabilized PD-L1 and suppressed the formation of GSK3β-β-TrCP-PD-L1 complex [145]. EGF increased PD-L1 expression by promoting glycosylation-induced GSK3β inactivation [145]. Additionally, in epithelial-mesenchymal transition, β-catenin transcriptionally induced the expression of N-glycosyltransferase STT3. The STT3 promoted PD-L1 N-glycosylation, stabilizing and upregulating PD-L1 [149]. Moreover, in glioma, FKBP51s (a co-chaperone) regulated PD-L1 expression by promoting glycosylation modification [150]. Overexpressing or silencing FKBP51s increased or decreased the level of glycosylated-PD-L1 [150].

Palmitoylation

Palmitoylation is a well-studied post-translational lipid modification. Palmitoylation at C272 increased PD-L1 stability by counteracting its ubiquitination [151, 152]. DHHC3 catalyzed C272 palmitoylation of PD-L1 [152]. Silencing DHHC3 enhanced antitumor immune response in vitro and in vivo [152].

Perspectives and conclusion

A growing body of evidence suggests that it is inaccurate to select patients merely by PD-L1 abundance. Understanding the difference between inflammation-induced PD-L1 and oncogenic signal-mediated constitutive PD-L1 is helpful to patient selection. For instance, for EGFR mutant NSCLC patients, α-PD-1 therapy’s efficacy was poor despite the high level of PD-L1 [153]. The EGFR mutation-driving NSCLCs commonly harbor lower mutation burdens, and the lower immunogenicity leads to the resistance to α-PD-1 treatments [43]. This oncogenic EGFR-mediated PD-L1 expression could not reflect the real status of the TME. Alternatively, a comprehensive framework containing multiple surrogate markers such as tumor mutation burden would be valuable for selecting patients and predicting outcomes.

Besides, agents regulating PD-L1 expression might have a synergistic effect with the current immune checkpoint inhibitors (Fig. 2). Targeting therapies such as CDK4/6 inhibitor upregulated PD-L1 expression and promoted immune escape [141, 146]. This treatment-induced immune evasion could be overcome by combination therapies containing α-PD-1/PD-L1. Besides, adjuvant treatment regulating PD-L1 expression might elevate the sensitivity to α-PD-1/PD-L1 or other immune checkpoint inhibitors [144, 145]. For example, metformin downregulated PD-L1 by promoting endoplasmic-reticulum-associated degradation, and the combination therapy of metformin and α-CTLA-4 exhibited a synergistic antitumor activity [144].

Generally, in the TME, the expression of PD-L1 is regulated by numerous factors, including inflammatory stimuli and oncogenic pathways at the levels of transcription, post-transcription, and post-translation.
Exploring potential PD-L1 regulators helps select patients and overcome resistance to α-PD-1/PD-L1 treatments. Besides, the agents regulating PD-L1 expression might be possible adjuvant therapies for the current immune checkpoint inhibitors.

**Abbreviations**

PD-1: Programmed cell death-1; PD-L1: Programmed death-ligand 1; TME: Tumor microenvironment; NSCLC: Non-small cell lung cancer; H3K4me3: Tri-methylation of histone H3 on lysine 4; H3K27me3: Tri-methylation of histone H3 on lysine 27; EZH2: Enhancer of zeste homolog 2; DNMTi: DNA methyltransferase inhibitors; HADC3: Histone deacetylase 3; IRF: Interferon-responsive factor; IFN: Interferon; PTPRO: Protein tyrosine phosphatase receptor type O; TNF-α: Tumor necrosis factor-α; EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor; MAPK: Mitogen-activated protein kinase; MHC: Major histocompatibility complex; PTEN: Phosphatase and tensin homolog; PI3K: Phosphoinositide 3-kinase; NF-κB: Nuclear factor kappa-B; ROS: Reactive oxygen species; HIF-1α: Hypoxia-inducible factor-1α; ALK: Anaplastic lymphoma kinase; EML4: Echinoderm microtubule-associated protein-like 4; BET: Bromodomain and extraterminal; DSB: Double-strand break; miRNA: MicroRNA; UTR: Untranslated region; CDK: Cyclin-dependent kinase; CTLA-4: Cytotoxic T Lymphocyte antigen 4; GSK3β: Glycogen synthase kinase 3β.

**Authors' contributions**

MY drafted the manuscript and prepared the figures. MN and LX collected the related references and participated in discussion. SL and KW designed this review and revised the manuscript. All authors contributed to this manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of China (No. 81874120, 82073370).

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 18 November 2020 Accepted: 17 December 2020**

**Published online: 07 January 2021**
References

1. Cha JH, Chan LC, Li CW, Hu J, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359–70.

2. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12:92.

3. Sun C, Madzard R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52.

4. Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of the microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2018;17:10.

5. Sutmame M, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313–26.

6. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cozzi L, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

7. Mutzer R, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell cancer. N Engl J Med. 2015;372:1521–32.

8. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2517–26.

9. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012), a multicentre, open-label, phase Ib trial. Lancet Oncol. 2016;17:717–26.

10. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu CR, et al. CheckMate 142: open-label, phase 2 study of nivolumab in advanced hepatocellular carcinoma (HCC). J Hematol Oncol. 2017;10:129.

11. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab versus durvalumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015–26.

12. Zhu T, Hu Z, Wang D, Jing H, Li R, Sun J, et al. Epigenetically silenced PD-L1 in colorectal cancer. Bioessays. 2017;39:1–12.

13. Murali S, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52.

14. Ikeda T, Tanaka T, Nakamura Y, Kiyohara Y, Hattori K, Fujiwara K, et al. Genetic, transcriptional and post-translational regulation of the programmed death ligand 1 (PD-L1). J Natl Cancer Inst. 2014;106:1528–40.

15. Yao S, Jiang L, Moser EK, Jewett LB, Wright J, Du J, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470–8.

16. Huang X, Yuan Q, Li P, Xu X, Zhang L, Zhao P, et al. Epigenetic silencing of PD-L1 in colorectal cancer cells. BioEssays. 2017;39:1–12.

17. Berti A, Del Vecchio A, Pintor M, Bono P, Mocchi L, Ghiringhelli F, et al. Genomic rearrangements involving programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) in CD274-negative or CD274-low colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:e1235–47.

18. Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death ligand 2 (PD-L2). J Exp Clin Cancer Res. 2017;36:158–66.

19. Shiraishi K, Saito M, Namba T, Oda S, Endo T, Umeda T, et al. The role of PD-L1 expression in gastric carcinoma. Sci Rep. 2017;7:17810.

20. Yao S, Jiang L, Moser EK, Jewett LB, Wright J, Du J, et al. Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection. Mucosal Immunol. 2015;8:746–59.
47. Blazin N, Cheng T, Carballal S, DiGiannati J. Activation of a protumorigenic IFNγ/STAT1/IRF1 signaling pathway in keratinocytes following exposure to solar ultraviolet light. Mol Carcinog. 2019;58(15):1656–69.

48. Yan Y, Zheng L, Liu Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;69:1891–903.

49. Shin DS, Zaretzky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovsk S, Kalsbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7:188–201.

50. Xu L, Chen X, Shen M, Yang DR, Fang L, Weng G, et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol Oncol. 2018;12:269–86.

51. Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer. 2020;8:e000385.

52. Lamano JB, Lamano JB, Li YQ, DíOmenýco D, Cho W, Veliccea D, et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin Cancer Res. 2019;25:3643–57.

53. Shen MJ, Xu LJ, Yang L, Tsai Y, Keng PC, Chen Y, et al. Radiation alters cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 2017;184:7–14.

54. Quandt D, Jasinski-Bergner S, Müller U, Schulze B, Seliger B. Synergistic effects of IL-4 and TNFα on the induction of B7–H1 in renal cell carcinoma cells inhibiting alloreactive T cell proliferation. J Transl Med. 2012;14:151.

55. Jiang C, Yuan F, Wang J, Wu L. Oral squamous cell carcinoma suppresses PD-L1 expression. J Cancer Res. 2017;2:151.

56. David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena S, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–63.

57. Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-β of lung cancer cells and is associated with regulatory T cell generation. Oncol Rep. 2012;28:615–21.

58. Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the Akt-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76:227–38.

59. Fiedler M, Schulz D, Piendl G, Brockhoff G, Eichberger J, Menevse AN, et al. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines. Exp Cell Res. 2020;396:112259.

60. Suh KS, Jung HJ, Kim JW, Han SH, Lee HS, Min A, et al. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget. 2017;8:63901–10.

61. Huang TY, Chang TC, Chin YT, Pan YS, Chang WL, Liu FC, et al. NDAT targets PI3K-mediated PD-L1 upregulation to reduce proliferation in gefitinib-resistant colorectal cancer. Cells. 2020;9:1830.

62. Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, et al. JAK2 mutations and PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol. 2012;122:295.

63. Akbay EA, Koyama S, Carretero J, Altabef A, Tichaeva JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–63.

64. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585–93.

65. Garassino MC, Gelber AJ, Grossi F, Chiaro R, Soto Parra H, Casciniu S, et al. Italian novelubam expanded access program in non-small non-small cell lung cancer patients: results in never-smokers and EGFR mutant patients. J Thorac Oncol. 2018;13:1146–55.

66. Arac alert. Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19:521–36.

67. Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13:113.
87. Xu D, Li J, Li R, Yang T, Xiao C, Gong P. PD-L1 expression is regulated by NF-κB during EMT signaling in gastric carcinoma. Onco Targets Ther. 2019;12:10099–105.

88. Li H, Xiao JQ, Zhu FS, Yi ZH, Pan CY, Wu XM, et al. LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation. J Cell Biochem. 2018;119:9997–10004.

89. Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017;36:4037–46.

90. Roux C, Jafari SM, Shinde R, Duncan G, Cescon DW, Silvester J, et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci U S A. 2019;116:4326–35.

91. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139–68.

92. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665–74.

93. Sellam LS, Zappasodi R, Chettibi F, Djennaoui D, Yahi-Ait Mesbah N, Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

94. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates hypoxia-mediated escape from adaptive immunity in cancer cells. Metabolism. Arch Biochem Biophys. 2020;690:108479.

95. Roux C, Jafari SM, Shinde R, Duncan G, Cescon DW, Silvester J, et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci U S A. 2019;116:4326–35.

96. Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2019;33:152–47.

97. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200-3ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:2541.

98. Sun C, Lan P, Han Q, Huang M, Zhang X, Xu G, et al. Oncoprotein gene SALL4 reactivation by hepatitis B virus counteracts miR-200C in PD-L1-induced T cell exhaustion. Nat Commun. 2018;9:1241.

99. Liu J, Xi Q, Wang H, Zhang Z, Li H, Cheng Y, et al. miR-18a-3p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem Biophys Res Commun. 2017;488:425–31.

100. Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016;7:11406.

101. Su N, Zhang X, Zhang Y. miR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1. Cell Mol Biol Lett. 2019;24:68.

102. Qu F, Ye J, Pan X, Wang J, Gan S, Chu C, et al. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. J Drug Target. 2019;27:67–74.

103. Xie WB, Liang LH, Wu KG, Wang LX, He X, Song C, et al. MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC. Cell Physiol Biochem. 2018;46:654–63.

104. Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27:443–52.

105. Liu J, Fan L, Yu H, Zhang J, He Y, Feng D, et al. Endoplasmic reticulum stress promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18:165.

106. Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: Going beyond transcriptional regulation. Mol Cancer. 2018;17:164.

107. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16:2829–37.

108. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18:2162–74.

109. Sato H, Niiim A, Yasuhara T, Permuta TM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751.

110. Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in immune escape. J Hematol Oncol. 2020;13:22.

111. Roux C, Jafari SM, Shinde R, Duncan G, Cescon DW, Silvester J, et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci U S A. 2019;116:4326–35.
132. Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L, et al. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med. 2018;22:3847–56.

133. Yoon CJ, Chang MS, Kim DH, Kim W, Koo BK, Yun SC, et al. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIA53/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas. Gastric Cancer. 2020;23:780–90.

134. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Ablation of RAB6A expression through 3’-UTR disruption in multiple cancers. Nature. 2016;534:402–6.

135. Coelho MA, de Carne TS, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47(1083–99):e6.

136. Yang K, Zhou J, Chen Y, Chen Y, Chen L, Zhang P, et al. Angiotensin II contributes to intratumoral immunosuppression via induction of PD-L1 expression in non-small cell lung carcinoma. Int Immunopharmacol. 2020;84:106507.

137. Wu Z, Huang R, Yuan L. Crosstalk of intracellular post-translational modifications in cancer. Arch Biochem Biophys. 2019;676:108138.

138. Choe ML, Sparbier CE, Chan YC, Williamon JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–5.

139. Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ. 2013;20:21–30.

140. Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:106–10.

141. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPD5 to control cancer immune surveillance. Nature. 2018;553:91–5.

142. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN. Cancer Cell. 2016;30:925–39.

143. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129:3324–38.

144. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71:660–20.e7.

145. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.

146. Li H, Li CW, Li X, Ding Q, Guo L, Liu S, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PD-L1. Gastroenterology. 2019;156(1849–61):e13.

147. Veillon L, Falah H, Abou-El-Hassan H, Kobeissy F, Mechref Y. Glycosylation changes in brain cancer. ACS Chem Neurosci. 2018;9:1–72.

148. Shi X, Zhang D, Li F, Zhang Z, Wang S, Xuan Y, et al. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. J Hematol Oncol. 2019;12:127.

149. Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908.

150. D’Arrigo P, Russo M, Rea A, Tufano M, Guadagno E, Del Basso De Carlo ML, et al. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget. 2017;8:68291–304.

151. Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019;29:83–6.

152. Yao H, Lan J, Li C, Shi H, Brousseau JP, Wang H, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3:306–17.

153. Lisberg A, Cummings A, Goldman JW, Bornayian K, Reese N, Wang T, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138–45.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.